Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
PeerJ Inc.
2013-02-01
|
| سلاسل: | PeerJ |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://peerj.com/articles/31.pdf |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|